SS31

The ss31 peptide ) is a significant synthetic mitochondrial-targeting peptide that has been extensively studied for its potential to treat diseases involving mitochondrial dysfunction.

Here’s a detailed breakdown of what you need to know:

What is ss31?

It is a small, water-soluble, aromatic-cationic tetrapeptide with the sequence 

D-Arg-Dmt-Lys-Phe-NH₂ (where Dmt is 2',6'-dimethyltyrosine). Its key features are:

• Mitochondrial Targeting: It is designed to freely cross cell membranes and accumulate several hundred-fold within the inner mitochondrial membrane (IMM), driven by the large negative charge (ΔΨm) inside.

• Mechanism of Action: It binds to cardiolipin, a unique phospholipid found almost exclusively in the IMM. Cardiolipin is crucial for the structure and function of mitochondrial electron transport chain (ETC) complexes. In conditions of stress, cardiolipin can be oxidized and lose its association with ETC proteins, leading to inefficiency and reactive oxygen species (ROS) production.

• Primary Proposed Mechanisms & Benefits

  By interacting with cardiolipin, ss31 is believed to:

  Stabilize Electron Transport Chain Supercomplexes: Improves the efficiency of cellular respiration (ATP production) and reduces electron "leakage."

  Reduce Oxidative Stress: By making the ETC more efficient, it drastically lowers the production of damaging reactive oxygen species (ROS).

  Inhibit Mitochondrial Permeability Transition Pore (mPTP) Opening: Helps prevent the collapse of mitochondrial function and the initiation of apoptosis (cell death).

  Improve Mitochondrial Fusion/Fission Dynamics: Promotes healthier mitochondrial networks.

  Primary Areas of Research & Clinical Trials

  SS31 has been investigated in a wide range of conditions where mitochondrial dysfunction is a key player:

• Cardiovascular:

  • Myocardial Infarction (Heart Attack): To reduce reperfusion injury when blood flow is restored.

  • Heart Failure: To improve the energy-deficient state of failing heart cells.

• Neurodegenerative Diseases:

  • Alzheimer's Disease: To improve neuronal bioenergetics and reduce oxidative damage.

  • Parkinson's Disease: To protect dopaminergic neurons.

  • Huntington's Disease: Models showed improved motor function and survival.

• Ocular Diseases:

  • Dry Age-Related Macular Degeneration (AMD): The most advanced clinical program. A topical eye drop formulation (SPI-1005) showed promise in improving visual function in a Phase 2 trial.

• Mitochondrial Myopathies: Such as Barth Syndrome, a genetic disorder linked to cardiolipin metabolism.

• Acute Kidney Injury: To protect renal tubule cells during ischemia.

• Aging & Frailty: To address the fundamental role of mitochondrial decline in aging.